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Background. Acute kidney injury (AKI) is a common but least studied complication of lymphoma. Objective. To determine the
frequency and predictors of AKI in lymphoma and to study the impact of AKI on hospital stay andmortality.Methods. Retrospective
review of medical records of hospitalized lymphoma patients aged ≥14 years between January 2008 and December 2011 was done.
Results. Out of 365 patients, AKI was present in 31.8% (116/365). Multivariate logistic regression analysis showed that independent
predictors for AKI included sepsis (odds ratio (OR) 3.76; 95%CI 1.83–7.72), aminoglycosides (OR 4.75; 95%CI 1.15–19.52), diuretics
(OR 2.96; 95% CI 1.31–6.69), tumor lysis syndrome (OR 3.85; 95% CI 1.54–9.59), and R-CVP regimen (OR 4.70; 95% CI 1.20–18.36).
AKI stages 2 and 3 was associated with increased hospital stay (OR 2.01; 95% CI 1.19–3.40). Conclusion. AKI was significantly
associated with sepsis, aminoglycoside, diuretics, presence of tumor lysis syndrome, and use of R-CVP regimen. Presence of AKIN
(Acute Kidney Injury Network) stages 2 and 3 AKI had increased hospital stay. AKI was also associated with increased mortality.
1. Introduction
Acute kidney injury (AKI) is a well-known complication of
cancer [1, 2]. Etiology of AKI in cancer varies from acute
tubular necrosis due to medication or sepsis, volume deple-
tion, tumor lysis syndrome, and obstruction or infiltration of
the kidneys. Presence of AKI leads to longer hospitalization
and increased cost [3, 4]. It also increasesmortality in patients
with cancer [1, 2], delays treatment, and increases toxicity of
chemotherapy.
Like all cancers, AKI can also occur in lymphoma. The
literature reports on AKI in lymphoma are limited to case
reports. Lymphoma patients are prone to develop AKI due
to acute tubular necrosis secondary to sepsis, nephrotoxic
medications, and contrast studies. Lymphomatous infiltra-
tion of kidneys [5, 6], light chain proximal tubulopathy [7],
membranous nephritis [8], membranoproliferative glomeru-
lonephritis [9], Fanconi syndrome [10], and tumor lysis
syndrome [11–13] have all been reported in the literature.This
is the first study done on AKI in lymphoma patients and aims
to determine frequency and predictors of AKI in lymphoma
and to study its impact on hospital stay and mortality.
2. Materials and Methods
2.1. Setting and Study Population. This is a retrospective case
series study conducted at the Aga Khan University Hospital
Karachi, Pakistan. Aga Khan University Hospital is a tertiary
care health facility located in the largest city of Pakistan,
Karachi, which has a population of around 15 million. It has
15 inpatient units with a total capacity of 563 beds. Data were
collected upon approval from the ethics review committee of
Hindawi Publishing Corporation
International Journal of Nephrology
Volume 2014, Article ID 272961, 6 pages
http://dx.doi.org/10.1155/2014/272961
2 International Journal of Nephrology
the institution. Study subjects included inpatients admitted
with a primary diagnosis of lymphoma. They were identified
from a central computerized record for a period of 4 years
from January 2008 to December 2011 with the help of the
Department of Health Information Management System.
Records of the cases were retrieved through codes using
International Classification of Diseases 9th Revision Clin-
ical Modification (ICD-9 CM) 201.90–201.98 for Hodgkin
lymphoma and 202.80–202.88 for non-Hodgkin lymphoma.
Study subjects included patients aged≥14 years admittedwith
the primary diagnosis of lymphoma, irrespective of type or
stage of disease. Patients with chronic kidney disease were
excluded. Patients were divided into two cohorts (those with
and those without AKI) in order to determine independent
predictors of AKI. Similarly, length of stay and mortality
inside hospital were also compared in these two cohorts. Data
on demographics, clinical features, laboratory data, length of
stay, recovery of renal functions, and mortality were noted.
We used the Acute Kidney InjuryNetwork (AKIN) definition
for classification of AKI stages [14]. AKI stage 1 was defined as
an increase in serum creatinine >26.5 𝜇mole/L (≥0.3mg/dL)
or 1.5- to 2-fold increase from baseline. AKI stage 2 was
defined as an increase in serum creatinine of >2-3-fold from
baseline. AKI stage 3was defined as an increase in serum
creatinine of>3-fold frombaseline or an absolute serum crea-
tinine of >354 𝜇mol/L (≥4mg/dL).
2.2. Definitions. Sepsis was defined as suspected or con-
firmed infection with the presence of two of the following:
(1) temperature > 38∘C or <36.5∘C;
(2) heart rate > 90 per minute;
(3) respiratory rate > 30 per minute;
(4) leukocyte count > 11000 or <4000.
Tumor lysis syndrome (Cairo-Bishop definition) was
defined as 2 of the following:
(1) uric acid> 8mg/dL or 25% increase from the baseline;
(2) potassium > 6mmol/L or 25 % increase from the base
line;
(3) phosphate > 4.5mg/dL;
(4) calcium < 7mg/dL or 25% decrease from the baseline
3 days before or 7 days afterward.
2.3. Data Analysis. Descriptive statistics were used to sum-
marize baseline values and demographic data. Quantitative
data were expressed as mean, median, interquartile range
and standard deviation (SD) and number of observations
with percentage (%), respectively. Evaluation of association
between outcomes (AKI and without AKI group, length of
hospital stay) and potential causative factors were used with
𝜒
2-test or Fisher’s exact tests of independence and Student’s 𝑡-
test. Odds ratios (OR) and their 95% confidence intervals (CI)
were estimated using binary logistic regression, with AKI and
length of hospital stay (≤7 versus >7 days) as outcomes. Mul-
tivariable models were constructed, including variables that
Table 1: Demographic characteristics of study population (𝑛 = 365).
Age, years, mean ± SD 50.3 ± 16.3
Gender, number (% )
Male 262 (71.8)
Female 103 (28.2)
Lymphoma, number (%)
HL (Hodgkin lymphoma) 87 (23.8)
NHL (non-Hodgkin lymphoma) 278 (76.2)
Mechanical ventilation, number (%) 23 (6.3)
Vasopressors, number (%) 31 (8.5)
Diuretics, number (%) 40 (11)
Vancomycin, number (%) 34 (9.3)
Amphotericin B, number (%) 16 (4.4)
Aminoglycosides, number (%) 14 (3.8)
Median baseline creatinine 0.8 (0.4–11.1)
Median (range) length of stay 2 (0–45)
Renal replacement therapy (%) 12 (3.3)
Tumor lysis syndrome (%) 28 (7.7)
Sepsis 64 (17.5)
AKI
116 (31.8)
AKI stage 1 = 78 (67.2%)
AKI stage 2 = 25 (21.6%)
Aki stage 3 = 13 (11.2%)
Mortality (%) 34 (9.3%)
showed an effect on the prediction of AKI and length of hos-
pital stay >7 days in the univariate analysis. All 𝑃 values were
based on two-sided tests and significance was set at a 𝑃 value
<0.05. The analyses were performed using SPSS version 19.
3. Results
3.1. General Characteristics of the Study Population. Out of
365 patients, two-thirds (71.8%) were male. Mean age was
50.13 ± 16.3 years. One hundred and sixteen (31.8%) patients
had AKI. Among patients with AKI, 78 (67.2%) had AKIN
stage 1, 25 (21.6%) had AKIN stage 2, and 13 (11.2%) had
AKIN stage 3. Sepsis was found in 64 (17.5%) and tumor
lysis in 28 (7.7%) of the patients. Furosemide, vancomycin,
amphotericin, and aminoglycoside were used in 40 (11%),
34 (9.31%), 16 (4.4%), and 14 (3.8%) patients, respectively.
Overall hospital mortality was 9.3% in AKI patients (Table 1).
3.2. Independent Predictors for AKI. We analyzed vari-
ous variables including antimicrobial and chemotherapeutic
agents used. Various chemotherapy regimen used included
R-CHOP (rituximab-cyclophosphamide, hydroxy daunoru-
bicin, oncovin, and prednisolone), CHOP (cyclophospha-
mide, hydroxy daunorubicin, oncovin, prednisolone), R-
CVP (rituximab-cyclophosphamide, vincristine, and predni-
solone), CVP (cyclophosphamide, vincristine, and pred-
nisolone), ABVD (adriamycin, bleomycin, vinblastine, and
dacarbazine) and DHAP (dexamethasone, high dose Ara C,
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Table 2: Univariate analysis of factors associated with progression of AKI (𝑛 = 365).
AKI, 𝑛 = 116 No AKI, 𝑛 = 249 𝑃 value
Age, in years 53.7 ± 15.5 48.7 ± 16.5 0.005
Gender
Male 82 (70.7) 180 (72.3) 0.75
Female 34 (29.3) 69 (27.7)
Hospital stay, median (range) 3 (1–17) 3 (1–14) 0.62∗
Baseline Cr, median (range) 0.8 (0.4–2.6) 0.8 (0.4–11.1) 0.39∗
Maximum Cr, median (range) 2 (0.9–11.3) 1 (0.6–25.9) <0.001∗
Stage of lymphoma
I 4 (9.3) 9 (9.1) 0.17
II 7 (16.3) 32 (32.3)
III 10 (23.3) 24 (24.2)
IV 22 (51.2) 34 (34.3)
Diuretics 24 (20.7) 16 (6.4) <0.001
Vancomycin 17 (14.7) 17 (6.8) 0.02
Amphotericin B 7 (6) 9 (3.6) 0.28
Aminoglycosides 11 (9.5) 3 (1.2) <0.001
Mechanical ventilation 12 (10.3) 11 (4.4) 0.03
Vasopressor 16 (13.8) 15 (6) 0.01
Chemotherapy
R-CHOP 26 (22.4) 68 (27.3) 0.31
CHOP 26 (22.4) 60 (24.1) 0.79
R-CVP 13 (11.2) 8 (3.2) 0.004
CVP 8 (6.9) 11 (4.4) 0.32
ABVD 12 (10.3) 42 (16.9) 0.11
DHAP 17 (14.7) 16 (6) 0.009
Sepsis 38 (57.6) 26 (17.2) <0.001
Tumor lysis 18 (15.5) 10 (4.0) <0.001
Hospital stay
≤7 days 72 (62.1) 202 (81.1) <0.001
>7 days 44 (37.9) 47 (18.7)
Mortality 17 (14.7) 17 (6.8) 0.02
∗Mann-Whitney 𝑈 test.
and cisplatin). R-CHOP, CHOP, and ABVD were the main
regimens used in 94, 86, and 52 patients, respectively. Uni-
variate analysis revealed increased age (𝑃 0.005), diuretics
(𝑃 < 0.001), vancomycin (𝑃 0.02), aminoglycoside (𝑃 <
0.001), R-CVP (𝑃 0.004), DHAP (𝑃 0.009), sepsis (𝑃 <
0.001), and tumor lysis (𝑃 < 0.001) as positive predictors
of AKI. However, multivariate logistic regression analysis
showed that independent predictors for AKI were sepsis (OR
3.76; 95% CI 1.83–7.72), aminoglycosides (OR 4.75; 95% CI
1.15–19.52), tumor lysis syndrome (OR 3.85; 95% CI 1.54–
9.59), and R-CVP regimen (OR 4.70; 95% CI 1.20–18.36)
(Tables 2 and 3).
3.3. Impact on Hospital Stay, Mortality, and Outcome at
Discharge. Patients with AKI stages 2 and 3 had statistically
increased hospital stay of greater than 7 days when compared
to those without AKI (OR 2.01; 95% CI 1.19–3.40). Mortality
was also high in patients with AKI (14.7%) when compared
to those without AKI (6.8%) (𝑃 0.03) (Table 4). Patients with
AKI who died were significantly associated with tumor lysis
Table 3: Factors predicting AKI.
OR [95% CI] 𝑃 value
Diuretic
No 1.0
Yes 2.96 [1.31–6.69] 0.009
Aminoglycoside
No 1.0
Yes 4.75 [1.15–19.52] 0.03
Sepsis
No 1.0
Yes 3.76 [1.83–7.72] <0.001
Tumor lysis syndrome
No 1.0
Yes 3.85 [1.54–9.59] 0.004
R-CVP
No 1.0
Yes 4.70 [1.20–18.36] 0.02
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Table 4: Impact of AKI on hospital stay and mortality.
Length of hospital stay
AKI stages 2, 3 >7 days No AKI >7 days Univariate analysis Multivariate analysis
21 (48.83%) 49 (19.52%) 𝑃 < 0.001 OR [95% CI 2.01 (1.19, 3.40)], 𝑃 0.008
Mortality
AKI No AKI Univariate analysis Multivariate analysis
17 (14.7) 17 (6.8) 𝑃 0.02
Table 5: Factors associated with mortality in AKI.
Outcome Death (𝑛 = 17) Alive (𝑛 = 99) 𝑃 value
Age, in years 54.3 ± 16 53.6 ± 15.4 0.85
Gender
Male (%) 8 (47.1) 74 (74.7) 0.04
Female (%) 9 (52.9) 25 (25.3)
Tumor lysis (%) 8 (47.1) 10 (10.1) 0.001
Ventilation (%) 8 (47.1) 4 (4) <0.001
Diuretic (%) 9 (52.9) 15 (15.2) 0.001
Vasopressor (%) 9 (52.9) 7 (7.1) <0.001
Sepsis (%) 17 (100) 21 (42.9) <0.001
Baseline creatinine 0.84 ± 0.22 0.84 ± 0.29 0.99
Stage of disease
I (%) 1 (16.7) 3 (8.1) 0.50
II (%) 1 (16.7) 6 (16.2)
III (%) 0 10 (27)
IV (%) 4 (66.7) 18 (48.6)
Table 6: Outcome of AKI at discharge.
Death 17 (14.7%)
Full recovery 45 (38.79%)
Partial recovery with no need of dialysis 40 (34.48%)
Persisting AKI with need of dialysis 14 (12.06%)
(𝑃 0.001), need of mechanical ventilation (𝑃 < 0.001),
diuretics (𝑃 0.001), and sepsis (<0.001) (Table 5).
Mortality in our cohort was 14.7%. Forty-three patients
(37.06%) with AKI fully recovered. Around 40 patients
(34.48%) had persisting AKI at discharge but did not need
dialysis. However 14 (12.06%) patients who needed dialysis
were still requiring dialysis at the time of discharge (Table 6).
4. Discussion
AKI is a well-known complication of cancer. However, very
little is known about AKI in lymphoma. To the best of our
knowledge, this is the largest report of AKI in lymphoma
patients. Our study revealed the presence of AKI in 31.8%
of patients. The incidence of AKI in various cancers has
been reported to be between 12 and 49% [15–19]. Our study
incidence is higher than that of Christiansen et al., who
reported incidence of AKI (defined as 50% elevation of base-
line serum creatinine) in 29.39% lymphoma patients [20].
The discrepancy could be explained by the noninclusion of
milder AKI patients in their study.
Our multivariate analysis identified sepsis, aminoglyco-
side usage, diuretics usage, tumor lysis syndrome, and R-
CVP usage as potential negative predictors. Cancer patients
may be immunocompromised due to multiple factors such
as chemotherapy, radiotherapy, impairment of normal leuko-
cyte function, or use of corticosteroids [21, 22]. The dysregu-
lation of their immune system predisposes patients to sepsis
which can lead to unregulated cytokine release and haemo-
dynamic disturbances. AKI usually ensues as a result of alter-
ations in renal perfusion resulting from pro-inflammatory
insults.
Diuretics usage may have a direct role in causing kidney
injury by exacerbating underlying hypovolemic and haemo-
dynamic state. It can also be argued that patients requiring
diuretic therapy are likely to have compromised heart or renal
function at baseline and, therefore,more likely to develop and
sustain kidney injury. On the other hand, it is possible that
diuretic therapy was initiated to maintain or increase urine
output in patients who may already have AKI. Aminoglyco-
side has been implicated in the development of kidney injury
in haematological malignancies. This could be related to its
direct nephrotoxic effects or through synergistic nephrotoxic
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activities with chemotherapy. The presence of sepsis which
may have necessitated the usage of aminoglycoside may also
have contributed to the risk of AKI.
We found tumor lysis syndrome in 7.7% of our study pop-
ulation. Various studies have reported spontaneous tumor
lysis syndrome in leukemia and lymphoma [11, 23–26].Hande
kjellstrand and his colleagues found tumor lysis in 42% of the
patients with lymphoma, which is higher than our result [23].
However, unlike our study Hande Kjellstrand et al. included
only high grade lymphomawhich has a greater propensity for
the development of tumor lysis syndrome.
Various chemotherapy regimens were used in our cohort
of patients. From our experience, the use of R-CVP regimen
was significantly associatedwithAKI. R-CVP regimen is used
for stages III andVI follicular lymphoma.High tumor burden
in stages III and IV follicular lymphoma with potential of
tumor lysis in combination with cyclophosphamide nephro-
toxicity might be a reason for this. Alternatively, combi-
nation of cyclophosphamide with vincristine may be more
nephrotoxic, which needs further exploration through future
studies. AKI in cancers causes significant morbidity and
mortality. Lameire et al. reported 3-month mortality of 30
percent [27]. Another study reported six-month mortality
of 73% in critically ill patients with cancer and AKI [28].
Lahoti et al. showed relatively mild elevation of creatinine
with worse mortality [29]. We in our study found mortality
of 14.7% in patients with lymphoma complicated with AKI as
compared to 6.8% in those without AKI. Similarly, presence
of AKI stages 2 and 3 in patients with lymphoma had more
propensity for a prolonged hospital stay.
We speculate that tumor lysis syndrome, concurrent sep-
sis with superimposed use of aminoglycosides, and diuretics
use make lymphoma patients prone to develop AKI. This
in turn results in more mortality and morbidity. Therefore,
patients with high grade lymphoma should be cautiously
watched during their chemotherapy as they can potentially
deteriorate by developing tumor lysis and subsequent AKI.
Similarly, sepsis should be vigorously looked for and treated
appropriately. While managing gram negative sepsis broad
spectrum, antibiotics other than aminoglycosides should be
chosen if possible. Patients with sepsis and tumor lysis are
often volume depleted and need aggressive fluid resusci-
tation. Therefore, diuretics use should be judiciously used
only in the presence of evident fluid overload. We can thus
potentially avoid AKI and hence can decrease mortality and
morbidity.
We acknowledge several limitations of our study. This
is a retrospective study based on data from a single centre.
Due to the retrospective nature of this study, etiology of AKI
was difficult to determine. Similarly, due to lack of long-
term followup of the patients, long-term impact of AKI on
lymphoma patients could not be determined. Multicentre
prospective studies with long-term followup are needed to
analyze etiology of AKI, its long-term outcome, and impact
on mortality and morbidity. Similarly, there is a need to
determine least nephrotoxic chemotherapy regimen through
prospective analysis. Judging by the results of this study, we
propose the following management considerations for high-
risk lymphoma patients:
(1) careful attention to haemodynamics and volume sta-
tus;
(2) avoidance of specific drugs;
(3) avoidance of tumour lysis with prophylacticmeasures
(e.g., prophylactic allopurinol/aggressive rehydration,
etc.);
(4) early identification and treatment of sepsis;
(5) choice of chemotherapy;
(6) early initiation of RRT (? debatable);
(7) early involvement of nephrology team;
(8) early involvement of intensivists.
5. Conclusions
AKI is common in lymphoma. Tumor lysis syndrome, sepsis,
and use of aminoglycoside and furosemide were associated
with development of AKI. Presence of AKI stages 2 and 3
resulted in increased mortality and prolonged hospital stay.
We feel that identification of these negative predictors and
early intervention can help to prevent or reduce the severity
of AKI.
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